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Objectives: Cilostazol improves walking distance and quality of life in patients with peripheral arterial disease (PAD). This
study assessed the vascular and biochemical effects of cilostazol therapy in PAD patients.
Methods: PAD patients were prospectively recruited to a randomized, double-blinded, placebo-controlled trial. Baseline
clinical data were recorded. Clinical assessment included measurement of arterial compliance, transcutaneous oxygen-
ation, ankle-brachial index (ABI), and treadmill walking distance. Blood analyses included a full blood panel, coagulation
screen, urea and electrolytes, liver function tests, estimated glomerular filtration rate, and lipid profiles. Quality of life
indices were recorded using validated generic and walking-specific questionnaires. All tests were performed at baseline, 6,
and 24 weeks.
Results: Eighty patients (53 men) were recruited from December 2004 to January 2006. The cilostazol group had a
significant reduction in the augmentation index compared with the placebo group at 6 weeks (19.7% vs 26.7%, P .001)
and at 24 weeks (19.7% vs 27.7%, P  .005). A paradoxic reduction in transcutaneous oxygenation levels was identified
in the cilostazol group for the left foot at 6 weeks and for the right foot at both 6 and 24 weeks. The ABIs were not
significantly different between treatment groups at baseline, 6 weeks, or 24 weeks for the left and right lower limbs. The
mean percentage change in walking distance from baseline improved more markedly in the cilostazol compared with the
placebo group for absolute claudication distance at 6 (78.6% vs 26.4%, P .20) and 24 weeks (173.1% vs 92.1%, P .27);
however, these failed to reach significance. Significant improvements in lipid profiles were demonstrated with cilostazol
therapy at 6 weeks (triglycerides, high-density lipoprotein [HDL]) and at 24 weeks (cholesterol, triglycerides, HDL, and
low-density lipoprotein). The cilostazol treatment group demonstrated significant improvements in the Short Form-36
(physical functioning, physical component score), Walking Impairment (distance and speed), and Vascular Quality of Life
(pain) indices at 6 and 24 weeks. Although cilostazol was associated with side effects in approximately one-third of
patients, most settled within 6 weeks, facilitating the continuation of therapy in >89%.
Conclusion: Cilostazol is a well-tolerated, safe, and efficacious treatment for PAD patients. It not only improves patients’
symptomatology and quality of life but also appears to have beneficial effects on arterial compliance, possibly through its
lipid-lowering property. ( J Vasc Surg 2009;49:1226-34.)Peripheral arterial disease (PAD) affects 20% of adults
aged 55 years, with an estimated 27 million affected in
North America and Europe.1 Claudication is the common-
est presenting symptom. Overall, claudication symptoms
deteriorate in 25% of all those affected, with rates of dete-
rioration at 7% to 9% in the first year, and then subsequently
at rates of 2% to 3% per year. This results in an eventual
critical limb ischemia incidence of 0.25 to 0.45 per 1000
people per year.2
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1226Cilostazol (Pletal; Otsuka Pharmaceutical Europe Ltd
Middlesex, UK) is a 2-oxo-quinolone derivative that is a
reversible, selective inhibitor of phophodiesterase-3A
(PDE-3A), with antiplatelet, antithrombotic, vasodilatory,
antimitogenic, and cardiogenic properties.3,4 Cilostazol
was first identified as a potent antiplatelet agent with vaso-
dilatory effects in Japan in the 1980s and is licensed as a
therapeutic agent to improve walking distances in patients
with PAD.5
The mechanism by which cilostazol exerts its beneficial
effects in patients with PAD is not clear. Cilostazol acts on
platelets, vascular smooth muscle cells, endothelial cells,
cardiomyocytes, and adipocytes through an elevation in
cyclic adenosine monophosphate levels (cAMP) levels by a
combination of the inhibition of intracellular PDE-3A and
extracellular adenosine uptake.4,6,7 Cilostazol has been
previously reported as an efficacious therapeutic agent for
initial and absolute walking capabilities.5,8 In addition to
improved walking distances, the ankle-brachial index (ABI)
was also increased after treatment with cilostazol.9
We hypothesized that cilostazol could attenuate dele-
terious atherosclerotic effects in nondiabetic PAD patients
through improvements in arterial compliance, resulting in
advantageous myocardial effects, and in transcutaneous
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eral arterial perfusion. The primary end point was walking
distance. Secondary end points included ABI, arterial com-
pliance, TcpO2, quality of life, and assessment of serum
lipid profiles.
METHODS
Patient recruitment. Men and nonpregnant women
between the ages of 30 and 90 attending the Belfast City
Hospital Vascular Out-Patient Department were consid-
ered for study participation. Patient recruitment com-
menced in December 2004 and continued until January
2006. The study was approved by the local Research Ethics
Committee.
Patients were suitable for inclusion if they had intermit-
tent claudication that had been stable for 3 months com-
bined with optimization of medical treatment with anti-
platelet and cholesterol-lowering therapies as well as no
previous administration of cilostazol.10 Intermittent clau-
dication was defined as reproducible muscle discomfort in
the lower limb produced by exercise and relieved by rest,
with an ABI of0.9.10 Before consideration for the clinical
study, all patients were provided with exercise advice from
our claudication clinic or during the initial outpatient hos-
pital consultation; however, this was unsupervised in the
community.
Patients were excluded if they had evidence of diabetes
or impaired glucose tolerance (identified from their initial
referral letter or from initial blood analyses as part of risk
factor modification), a current or previous history of acute
or critical limb ischemia,10 an endovascular or surgical
procedure6 months preceding, a history of dementia, or
evidence of a comorbidity that would limit walking before
the onset of claudication pain as documented during pre-
vious treadmill assessments, such as severe angina, respira-
tory disease, or joint dysfunction secondary to inflammat-
ory or degenerative arthritis. Patients were also excluded if
they had a predisposition to bleeding or a history of uncon-
trolled cardiac, respiratory, renal, or liver disease, or if they
were taking omeprazole and diltiazem, as described in the
cilostazol safety guidelines.11
Patient assessment. Each patient completed two
baseline assessments 4 weeks apart to facilitate a stabiliza-
tion run-in period before treatment allocation at time 0
weeks. After written informed consent, patients were ran-
domized in groups of four patients to receive cilostazol
(100-mg) treatment or matched placebo twice a day orally.
Both the investigator and patient were blinded to treatment
allocation. Follow-up clinical assessments were then per-
formed at 6 and 24 weeks.
Vascular assessment: Clinical examination. Clinical
assessment included the measurement of pulse rate, blood
pressure, and peripheral oxygen saturations.
Ankle-brachial indices. The ABI was derived from
brachial, posterior tibial, and dorsalis pedis artery systolic
pressures, which were measured using cuff occlusion by a
sphygmomanometer (BoSo Classico Aneroid Sphyg-
moand, Medisave, UK) and Doppler ultrasound (SuperDopplex II Huntleigh Healthcare, UK). The ABI was
calculated as the quotient of the highest ankle pressure of
each of the lower limbs divided by the highest brachial
pressure of the upper limbs. The assessment was performed
after 10 minutes of rest in the supine position.
Arterial compliance. Central ascending aortic pres-
sure waveforms were derived and analyzed using the
SphygmoCor system (PWV Medical, Sydney, Australia),
which uses noninvasive pulse wave analysis methodology to
assess arterial compliance.12-15 Pulse wave analysis mea-
surement was determined through accurate recordings of
the radial pressure wave that was calibrated against the
brachial artery.16 This arterial pressure wave was recorded
using applanation tonometry, which measures pressure
within the artery by determining the force needed to flatten
the artery.
Once the applanation tonometry reading had been
recorded at the radial artery, a computerized assessment of
arterial compliance was formulated. This ascending aortic
pressure waveform was generated through a generalized
transfer function that was calculated automatically by the
SphygmoCor system software.17-19 The transfer function
between the ascending aorta and radial artery has been
reported as a relatively constant phenomenon in adult
humans.16 Results using a generalized transfer function
have been reported to approach a90% accuracy in gener-
ating features of the ascending aortic pressure wave.16
Further description of this technique and validation of this
methodology has been previously reported by our unit.20
Transcutaneous oxygenation. The TcpO2 assess-
ment was performed on the dorsum of each foot in the
webspace between the first and second toes as well as on the
chest wall as a reference lead using the TCM400 monitor-
ing system (Radiometer, West Sussex, UK).21
Biochemical assessment. Blood samples for full
blood count, coagulation screen, electrolytes, and liver
function tests were collected before exercise. All patients
attended at the same time for each assessment but were not
routinely fasted. All assays were performed routinely by the
laboratories of the Belfast City Hospital. An estimation of
glomerular filtration rate (eGFR) was performed for each
assessment from calculations based on the serum creatinine
levels using an online-calculator derived from the UK
Chronic Kidney Disease (CKD) eGuide on the Renal As-
sociation Web site (http://www.renal.org/eGFRcalc/
GFR.pl). This online tool calculated an eGFR value by
using the patient’s serum creatinine level, sex, age, and race.
Walking assessment. A 30-minute rest period was
provided prior to the commencement of the treadmill test.
This was performed on a calibrated treadmill (Mortara
Xscribe Treadmill, Mortara Instrument Inc, Milwaukee,
Wisc) at a constant speed of 2 mph (3.2 kph) and a 10%
gradient.10 The initial claudication distance (ICD) was
defined as the distance when the patient first reported the
onset of claudication symptoms. The distance walked until
the patients were unable to continue because of claudica-
tion pain was described as the absolute claudication dis-
tance (ACD). All treadmill tests were performed by the
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environment.
Quality of life. The generic Short-Form 36 (SF-36),
Disease-Specific Walking Impairment Questionnaire (WIQ),
and Vascular Quality of Life (VascuQoL) instruments were
used to assess quality of life.22 The self-administered ques-
tionnaires were given to every patient after each treadmill
test, with an adequate time of 10 to 50minutes to complete
the questionnaires. A spreadsheet was used to analyze the
questionnaire results after all patients had completed the
study.
The SF-36 subscales were scored on a scale of 0% to
100%, where 0% is the lowest level of functioning and 100%
the highest.23 The WIQ responses to individual items
within distance and speed categories were aggregated
within a category to a single summary score. Speed and
distance summary scores ranged from 0% to 100%.24 The
VascuQoL total score was defined as a mean total for all
answered questions with a minimum score of 1 indicating
worst quality of life and a maximum score of 7 indicating
best quality of life.22
Statistical analysis. Quantitative end points for each
variable were analyzed at each of the four assessment times
(4, 0, 6, and 24 weeks). Descriptive statistics for baseline
variables were calculated as the mean and standard error of
the mean (SEM) or the median and interquartile ranges
(IQR). We assessed each measurement parameter with a
Q-Q plotting to ascertain the presence of normally distrib-
uted data. All of the variables did not conform to the
normal distribution; therefore, nonparametric methodol-
ogy was used to analyze the data. The Mann-Whitney U
(MWU) test was used to compare differences between the
cilostazol and placebo groups. The Wilcoxon signed rank
test (WSR) was used to compare differences within treat-
ment groups to baseline. All statistical tests were two-sided
and differences were considered significant at a value of P
05. Statistical analysis was performed using the SPSS 12
software (SPSS Inc, Chicago, Ill).
Owing to the absence of previous studies assessing the
effects of cilostazol on arterial compliance and TcpO2, our
study was performed on an intention-to-treat principle with
the power calculation derived fromwalking distance indices
reported by Dawson et al.25 Therefore, 30 patients per
group completing the trial would have a 90% power to
detect a statistically significant (P  .05; two-tailed) differ-
ence in change in maximal walking distance between
groups of magnitude of 45 meters. This assumes a mean
baseline maximal walking distance of 150 meters and a
standard deviation of 54 meters, and an improvement of
30% in one group and no change in the other.25 A further
12 patients would also be recruited to a total of 72 patients
to account for a 20% dropout rate.
RESULTS
Patient recruitment. The study successfully recruited
80 patients who were randomized to receive cilostazol or
placebo (see Fig for recruitment algorithm). These patientswere not significantly different for baseline medical comor-
bidities and walking capabilities (Table I).
Vascular assessment
Clinical examination. There was no significant differ-
ence between the cilostazol and placebo groups at baseline
for resting pulse, blood pressure, and cutaneous fingertip
oxygen saturations. A significant rise was noted in resting
pulse rate measurement in the cilostazol group compared
with placebo at both 6 (88 vs 79 beats/min; P  .01) and
24 weeks ( 87 vs 76 beats/min; P .005). Compared with
baseline, patients receiving cilostazol treatment demon-
strated a significant rise in resting pulse rate at both 6 and
24 weeks (P  .001 and P  .001) compared with no
difference when the placebo group was compared with
baseline (P  .61 and P  .83). There was no difference
between treatment groups’ resting blood pressure and fin-
gertip oxygen saturations at 6 and 24 weeks.
Ankle-brachial indices. No significant difference
was noted in the ABIs between and within treatment
groups at baseline, 6, or 24 weeks for left and right lower
limbs (Table II).
Arterial compliance. The baseline augmentation in-
dex was similar in the cilostazol and placebo groups (27.7%
vs 29.2%, P .08). A reduction in the augmentation index
was found in the cilostazol group compared with the pla-
cebo group after 6 weeks (19.7% vs 26.7%, P  .001) and
24 weeks (19.7% vs 27.7%, P  .005; Table II). There was
no difference between and within groups in time to wave
reflectance or subendocardial viability rate at any of the
time points.
Transcutaneous oxygenation. The baseline TcpO2
levels were similar in both groups. No difference was found
between treatment groups at 6 or 24 weeks (Table II). A
significant reduction in the cilostazol group TcpO2 indices
Normoglycaemic patients with peripheral 
arterial disease 
Medically fit with prior optimisation of 
medical treatment 
(n=561)
Personal Reasons 
(n=92)
Failure to Attend Out-Patient 
Department
(n=389)
RECRUITED TO STUDY 
(n=80)
Fig. Patient recruitment algorithm for normoglycemic patients
with peripheral arterial disease.in the left foot (LF) was noted at 6 weeks and in the right
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LF, P .02; RF, P .045) and 24 weeks (CWR, P .14;
LF, P  .16; RF, P  .044) compared within groups with
baseline. There was no difference at 6 (CWR, P .53; LF,
P  .86; RF, P  .10) and 24 weeks (CWR, P  .48; LF,
P  .82; RF, P  .14) when the placebo TcpO2 indices
were compared with baseline.
Hematologic and biochemical assessment
No difference was observed in the full blood count,
coagulation screen, electrolytes, liver function test, and
eGFR within and between groups except for a significant
increase in platelet count in the cilostazol group at 6 weeks
compared with placebo (281 vs 239  109/L , P  .04);
however, this difference was lost at 24-weeks (273 vs 232
109/L , P  .11).
Lipid profiles. The baseline levels of all the lipid com-
Table I. Patient comorbidities and walking capabilities for
Variable
Patients, No.
Sex, No.
Male
Female
Age, median (IQR), y
Male 65
Female 63
Medical history, No.
Hypertension
Hypercholesterolemia
Angina
Myocardial infarction
Coronary artery bypass grafting
Cerebrovascular accident
Carotid endarterectomy
Abdominal aortic aneurysm
Arterial bypass/endovascular intervention
Walking capabilities, No.
Limb affected
Left
Right
Both
Symptoms, median (IQR)
Duration, y 3.0
Deterioration, mon 6.0
Distance, median (IQR), m
Claudication onset 200
Maximal walking distance 225
Baseline ABI, median (IQR)
Left 0.86
Right 0.85
Smoking history, No.
Smoking status
Never smoked
Former smoker
Current smoker
Cigarette packs/day,a median (IQR) 1.0
Smoking duration,b median (IQR), y 40
Pack-yearsb 40
IQR, Interquartile range.
aRefers to current smokers.
bRefers to both current and ex-smokers (Mann-Whitney U test).ponents were similar in both groups except for low-densitylipoprotein (LDL), which was significantly higher in the
placebo group. A significant reduction in the cholesterol
concentration was found in the cilostazol group at 24
weeks, whereas significant reductions in triglyceride levels
were identified at 6 and 24 weeks compared with the
placebo group (Table III).
The high-density lipoprotein (HDL) levels significantly
increased in the cilostazol group at 6 weeks but not at 24
weeks compared with the placebo group. However, when
the mean percentage change from baseline in HDL levels
was considered, a significant improvement was demon-
strated at both 6 weeks (14.9% vs 0.4%, P .001) and at 24
weeks (12.0% vs 0.5%, P  .038) when the cilostazol and
placebo groups were compared. A significant reduction in
LDL concentrations was also demonstrated in the cilosta-
zol group compared with placebo at 24 weeks (Table III).
Walking assessment. The two groups were similar for
moglycemic patients with peripheral arterial disease
azol Placebo P
41 .99
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144.4 vs 138.6 m (P  .59). Both ICD (105.5 vs 67.5 m,
P  .019) and ACD (193.1 vs 168.5 m, P  .043)
significantly improved at 6 weeks for the cilostazol group
compared with placebo. No difference was noted between
treatment groups for ICD (82.7 vs 85.0 m, P  .98) and
ACD at 24 weeks (286.1 vs 227.1 m; P  .22).
When the 6- and 24-week levels were compared within
Table II. Clinical variables for normoglycemic patients wi
Variable Time C
ABI
Left Baseline 0.86 (
6 wks 0.86 (
24 wks 0.82 (
Right Baseline 0.85 (
6 wks 0.93 (
24 wks 0.80 (
Arterial compliance
AugIx, % Baseline 27.7 (
6 wks 19.7 (
24 wks 19.7 (
TR, ms Baseline 133.8 (
6 wks 135.3 (
24 wks 136.3 (
SEVR, % Baseline 142.2 (
6 wks 145.2 (
24 wks 143.3 (
TcpO2, kPa
CWR Baseline 7.8 (
6 wks 7.3 (
24 wks 6.3 (
Left foot Baseline 7.6 (
6 wks 6.1 (
24 wks 6.5 (
Right foot Baseline 6.5 (
6 wks 6.0 (
24 wks 5.2 (
ABI, Ankle-brachial index;AugIx, augmentation index;CWR, chest wall ref
TR, time to wave reflectance.
aData are presented as median (interquartile range) and analyzed by the Ma
bP  .001 and cP  .05 and equates to a significant reduction for the param
Table III. Lipid profiles for normoglycemic patients with
Variable, mg/dL Time Cil
Cholesterol Baseline 162.3 (1
6 wks 162.3 (1
24 wks 154.6b (1
Triglycerides Baseline 145.1 (1
6 wks 117.5c (8
24 wks 105.9c (8
HDL Baseline 54.1 (4
6 wks 58.0c (4
24 wks 61.9c (4
LDL Baseline 77.3 (6
6 wks 77.3 (6
24 wks 65.7d (5
HDL, High-density lipoprotein; LDL, low-density lipoprotein.
aData are presented as the median (interquartile range) and analyzed by Ma
bP  .02, cP  .001, and dP  .05 equates to a significant improvement fogroups with baseline, a significant improvement was notedin ICD and ACD for both the cilostazol (ICD: P .001 at
6 weeks, P .021 at 24-weeks; ACD: P .001 at 6 weeks,
P .001 at 24 weeks) and placebo groups (ICD: P .002
at 6 weeks, P  .001 at 24 weeks; ACD: P  .001 at 6
weeks, P  .001 24 weeks). The mean percentage change
in walking distance from baseline improved more markedly
in the cilostazol compared with the placebo group for ICD
(40.5% vs 26.6%; P  .25) and for ACD (78.6% vs 26.4%;
ripheral arterial diseasea
zol Placebo P
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though these failed to reach significance (Table IV).
Quality of life
SF-36 questionnaire. There were significant im-
provements in the mean percentage change from baseline
in the cilostazol group for the physical functioning (11.0%
vs –0.3%, P  .013) and physical component summary
(11.4% vs 5.1%, P  .044) subset scores at 24 weeks
(Table V). No significant improvement occurred in any of
the other SF-36 subsets compared with baseline for the
cilostazol or placebo groups at 6 and 24 weeks.
Walking Impairment Questionnaire. At the base-
line assessment, there was no significant difference be-
tween the cilostazol and placebo groups for both the
distance (39% vs 34%, P  .67) and speed (29% vs 34%,
Table IV. Walking distances for normoglycemic patients w
Treatment Patients, No.
ICD, m
Pre Post % C
Cilostazol 39 69.7 82.7 8
Placebo 41 63.5 85.0 6
ACD, Absolute claudication distance; ICD, initial claudication distance.
aData are presented as median and analyzed by Mann-Whitney U test.
Table V. Mean percentage improvement from baseline fo
peripheral arterial diseasea
Questionnaire Time
Short-Form 36
Physical Function, % 6 wks
24 wks
Role Physical, % 6 wks
24 wks
Body Pain, % 6 wks
24 wks
General Health, % 6 wks
24 wks
PCS, % 6 wks
24 wks
Total, % 6 wks
24 wks
VascuQol
Activity 6 wks
24 wks
Symptom 6 wks
24 wks
Pain 6 wks
24 wks
Emotion 6 wks
24 wks
Social 6 wks
24 wks
Total 6 wks
24 wks
PCS, Physical Component Score.
aData are presented as the mean (standard error of the mean) Mann-Whitn
bP  .01, cP  .001 and dP  .05 equate to a significant improvement forP  .38) components of the WIQ. There was no differ-ence between the treatment groups at 6 weeks (distance,
37% vs 35%, P  .64; speed, 33% vs 33%, P  .73) or at
24 weeks (distance, 38% vs 37%, P  .41; speed, 39% vs
38%, P  .88). However, when distance and speed
components were compared with baseline separately
within groups at 24 weeks, a significant improvement
had occurred in the distance and speed scores for the
cilostazol group compared with no change in the placebo
group (distance, P  .014 vs P  .81; speed, P  .021 vs
P  .74).
VascuQoL questionnaire. No difference was found
between the two groups for any of the VascuQoL subset
scores at any time point (Table V). However, when within-
group levels were compared with baseline, there was a
significant improvement in the VascuQoL pain subset for
the cilostazol group at 6 (P  .036) and 24 weeks (P 
peripheral arterial diseasea
ACD, m
P Pre Post % Change P
.63 144.4 286.1 173.1 .27
138.6 227.1 92.1
lity of life indices for normoglycemic patients with
ilostazol Placebo P
4.5 (3.3) 0.1 (2.7) .29
1.0 (4.5)b 0.3 (3.1) .013
4.2 (3.5) 1.6 (3.1) .91
7.8 (4.3) 5.4 (3.9) .62
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and 24-week levels were compared with baseline.
Tolerability of cilostazol. The 80 patients reported
43 medication-related adverse effects during the 24 weeks
of the clinical trial, and 36 of the 43 side effects were noted
in the cilostazol group. All were recognized adverse effects
associated with cilostazol therapy (headache, diarrhea, and
palpitations). However, as specified by the manufacturer of
cilostazol, most (34 of 36) had settled by the 6-week
assessment. Nine patients withdrew from the trial during
the course of the study. Six of these withdrew from the
cilostazol group, of which four were secondary to recog-
nized adverse effects.
DISCUSSION
Arterial stiffening, corresponding to a reduction in
arterial compliance, occurs with aging and is associated
with hypertension, diabetes, hypercholesterolemia, and
cigarette smoking.26 An increase in arterial stiffness results
in a higher velocity and amplitude of pulse wave generated
by the heart. This leads to larger reflected waves reaching
the ascending aorta earlier, augmenting the central systolic
pressure.27 Augmentation of this central systolic pressure
increases left ventricular workload and subsequent myocar-
dial oxygen demand.20
Previous studies have demonstrated improvements in
arterial compliance in patients with type 2 diabetes after 4
weeks of oral ascorbic acid therapy.20 This recent study has
also demonstrated a similar advantageous effect on arterial
compliance with cilostazol therapy as early as 6 weeks
continuing to 24 weeks, where a significant reduction in
the augmentation index suggested an overall reduction in
systemic arterial stiffness. Although there was no significant
difference between groups for time to wave reflectance and
subendocardial viability rate, a trend for improvement in
both these indices was observed at 24 weeks, suggesting
that cilostazol has a potential to increase aortic compliance
and reduce myocardial ischemia. Similar to ascorbic acid,
how cilostazol exerts these effects on arterial compliance
remains unclear. Possible mechanisms of action include
improvements in nitric oxide bioactivity due to the free
radical scavenging or from the antioxidant preservation
properties of cilostazol.28
Measurements of TcpO2 can be used to assess and
monitor PAD progression and evaluate the effect of any
therapeutic intervention.29,30 However, it has been mainly
studied in patients with severe PAD (Leriche-Fontaine
stage III and IV).31 De Groote et al31 compared the use of
TcpO2 and ABI assessments in 111 patients with intermit-
tent claudication and demonstrated no correlation between
these two assessment tools. They also documented that
maintenance in skin microcirculation with no change in
TcpO2 level, despite a significant reduction in ABI after
walking, may be seen, especially in the early recovery phase.
We demonstrated no difference in peripheral TcpO2 levels
between the two groups.
Contrary to previous reports regarding maintenance of
skin microcirculation after exercise in patients with inter-mittent claudication, an actual reduction in TcpO2 level
was observed when the mean percentage change from
baseline was considered. The exact reason for this reduction
is unclear and may be related to the ability of the cilostazol
group to walk further than the placebo group resulting in
greater and more sustained anaerobic metabolism with
shunting of cutaneous microcirculation.
As previously noted, cilostazol has significant beneficial
effects on plasma lipids, with a 15.8% reduction in triglyc-
erides and a 12.8% increase in HDL at 24 weeks.5 We also
demonstrated these advantageous effects on lipid ho-
meostasis, with beneficial effects on triglyceride and HDL
at both 6 and 24 weeks, and further beneficial effects in
cholesterol and LDL at 24 weeks. These effects on the
different lipid components in bloodmay have some bearing
on the improvement in arterial compliance. It has been
suggested that cilostazol may behave like statins, which
have been shown to cause regression of atherosclerotic
thickening, thus leading to a potential return of vessel wall
compliance.32 However, such a relationship remains uncer-
tain because post hoc correlation of lipid profiles with
arterial compliance indices did not demonstrate any signif-
icant correlation.
The assessment of ABI in PAD patients remains an
important screening tool. Although ABI is helpful, its use
for the assessment of treatment response is limited because
patients can frequently improve walking distances without
any significant change in ABI.33 Mohler et al9 reported
significant improvements in pre-exercise ABI at 16 weeks
with 100 mg of cilostazol twice a day and at 24 weeks with
both 50-mg and 100-mg twice-daily regimens. Our study
did not demonstrate any difference in ABI levels between
treatment groups at 6 or 24 weeks. An ABI change of0.1
is usually of minimal clinical significance, and therefore,
only large shifts in ABI are deemed clinically important.34
Few studies have demonstrated such gross treatment ef-
fects, including the study of Mohler et al,9 where the
maximal ABI increase was only 0.05.
An assessment of a postexercise ABI to construct an
ischemic window might have been worthwhile. This isch-
emic window is a function of both the degree of postexer-
cise ankle pressure reduction and the time required for the
ankle pressure to return to the pre-exercise level.35 Mohler
et al9 documented further important assessment parame-
ters in their review of 909 patients where cilostazol signif-
icantly reduced the “ischemic burden,” which is defined as
hemodynamic recovery time after exercise. Insofar as phar-
macologic therapy in PAD often requires a lengthy period
of time before anymeasurable beneficial effect is detectable,
a longer duration of treatment assessment in our patients
may also have been preferable.
Cilostazol is an efficacious therapeutic agent for the
treatment of PAD when the primary outcome measures are
walking distances. These improvements in walking distance
were observed as early as 4 weeks after cilostazol treatment
in patients with moderately severe and stable claudication,
with further improvements continuing to 24 weeks.36 A
meta-analysis by Thompson et al5 reported significantly
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60% and 67% increase in ICD for patients who received
cilostazol at 50 mg and 100 mg twice daily compared with
a 40% increase in ICD for the placebo treatment group.
The mean ACD of patients taking a placebo increased to
21.4% over baseline, whereas patients taking cilostazol 50
mg or 100 mg twice daily had increases in mean walking
distance of 44% and 50%, respectively.
Our study confirmed similar early improvements at 6
weeks in both ICD and ACD for normoglycemic patients
with PAD treated with cilostazol compared with placebo.
Although this difference was more subtle for ICD at 24
weeks, there was a marked improvement in ACD for the
cilostazol group at 24 weeks. However, it should be high-
lighted that the improvement in absolute claudication dis-
tances was not statistically significant between treatment
groups.
Our study also demonstrated a significant percentage
improvement in the cilostazol group for SF-36 physical
functioning and physical component summary subset
scores. Similar improvements in quality of life were also
demonstrated in the meta-analysis by Thompson et al,5
who reported a greater improvement in the SF-36 physical
function subscale and overall indices for the cilostazol
group compared with placebo. Further significant improve-
ments were noted in the bodily pain and physical subscales.
Similar to our findings, however, they reported nonsignif-
icant changes in the general health subscale.
Regensteiner et al24 and Thompson et al5 have both
reported that patients treated with cilostazol walked faster
and farther with less severe claudication pain as determined
by WIQ scores. Our study demonstrated a significant im-
provement in the cilostazol group for WIQ distance and
speed categories compared with baseline within groups at
24 weeks. The VascuQoL questionnaire pain subset also
significantly improved in the cilostazol group at both 6 and
24 weeks compared with baseline scores within-groups. In
this study, subjective improvements in patient quality of life
were found to be a delayed phenomenon, as minimal, if
any, change was identified at the 6-week assessment point.
Such beneficial quality of life traits only became apparent at
24 weeks. From a review of cilostazol PAD-related studies,
most other published reports only documented the quality
of life measurements on trial completion where the assess-
ment timelines ranged between 12 and 24 weeks.5,25,36
In our study, we found that the use of multiple ques-
tionnaires was a somewhat draining experience for the
patients who, on occasions, required between 40 and 60
minutes to complete all three questionnaires. Although
early quality of life assessment may still be appropriate for
endovascular or operative interventional studies, we con-
cluded that in pharmacologic clinical trials, only baseline
and trial completion questionnaires need to be completed,
without the addition of early parameter assessments. We
also suggest that only one questionnaire is required rather
than three separate tools and recommend the VascuQol
Questionnaire. This is a PAD-specific instrument with ac-
ceptable construct and convergent-divergent validity todetect the mild and moderate clinical improvements that
are commonly encountered in pharmacologic PAD studies.
Adverse effects of cilostazol such as loose stools, diar-
rhea, dizziness, palpitations, and particularly, headache, as a
result of vasodilatory properties, occur in up to 32% of
patients.37 We identified a significant rise in resting pulse
measurements with cilostazol therapy at both 6 and 24
weeks. This is most likely related to the cardiogenic prop-
erties of cilostazol and may possibly relate to why patients
experience palpitations during cilostazol therapy. There
was no significant difference in the 6-week and 24-week
resting blood pressure and fingertip oxygen saturations.
We recorded 43 medication-related adverse effects in
this clinical trial, and although most were identified in the
cilostazol-treated group, approximately one-quarter oc-
curred in the placebo group. These side-effect profiles are
similar to those in the literature, and as previously noted by
other workers, most side effects settle after 6 weeks.5,37 In
our study, cilostazol was well tolerated, with only four
(10.3%) patients discontinuing therapy due to side effects.
Cilostazol was also shown to have no significant detrimen-
tal effects in hematologic or biochemical indices, including
liver function tests.
CONCLUSIONS
This study confirms that cilostazol is a well-tolerated,
safe, and efficacious treatment for the improvement of
initial and absolute claudication distances in normoglyce-
mic PAD patients, with beneficial effects occurring at 6
weeks and further improvements continuing to 24 weeks.
Cilostazol also has additional beneficial effects, with im-
provement in arterial compliance and lipid profiles. How-
ever, no significant benefits were demonstrated in ABI or
peripheral TcpO2. Despite a wide interindividual and intra-
individual variation in the measurement of quality of life in
PAD patients, this study demonstrated a predominantly
subjective physical improvement in cilostazol-treated pa-
tients. Although cilostazol therapy is associated with a
relatively high frequency of side effects, most resolved 6
weeks and only resulted in the discontinuation of the drug
in 10.3% of patients.
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